PBM Sector Could Be Poised for ‘Profound Transformation’
-
Jul 24, 2025
In recent years, a harsh spotlight has been trained on PBMs, which stand accused of inflating the cost of prescription drugs and engaging in opaque business practices. While federal legislative reform has repeatedly foundered, state-based PBM regulations are proliferating. Meanwhile, the country’s three dominant PBMs have rolled out revamped models aimed at answering calls for rebate pass-through, simplicity and transparency.
With all those moving parts, what lies ahead for an embattled industry, which includes disruption-minded startups as well as the oft-criticized, vertically integrated CVS Caremark, Express Scripts and Optum Rx?
“There’s a frustration with the business practices, but I do think it’s addressable,” says Dan Mendelson, CEO of Morgan Health and founder of the consulting firm Avalere. “When the nursing home industry had all sorts of problems, they figured out a regulatory construct that was going to work for them and work for the government, and we’re at one of those points right now [with PBMs].”
For Radar on Drug Benefits’ final issue, we asked industry experts what they think is in store for the PBM sector — in terms of reform, innovation, diversification and more.
Read more© 2025 MMIT
